BridgeBio Pharma, Inc. (BBIO) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
BridgeBio Pharma, Inc. (BBIO)
A forensic read on BridgeBio Pharma, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-14.2
Altman Z-score
Watch
Earnings quality
4
Forensic signals
-206.7%
ROE
$13.7B
Market cap
BridgeBio Pharma, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -14.2, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
101d DSOReceivables vs revenue.Days sales outstanding moved from 8 to 101 days FY2024→FY2025 (receivables +2853% vs revenue +126%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections.
-531%Return on invested capital.Return on invested capital is -531% and slipping from -324% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+10.0%/yrShare-count dilution.Diluted share count changed +30% over the last 3 years to FY2025 (+10.0%/yr). The count is GROWING — existing holders are being diluted. That's ~10.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~30%.
26% of revStock-based comp load.Stock-based compensation ran 26% of revenue in FY2025 — about $0.69 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-146.0%
Free Cash Flow$-447.0M
Latest Revenue$502.1M
Revenue Growth YoY+126.3%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on BridgeBio Pharma, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about BBIO's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown